A Y Combinator-backed startup just raised $39 million to develop new psychedelic treatments for depression
Jonathan Sporn is the founder and CEO of Gilgamesh Pharmaceuticals. Gilgamesh Pharmaceuticals Gilgamesh Pharmaceuticals wants to develop the next generation…